Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development.
Chordoma is the fourth most common malignant primary neoplasm of the skeleton and almost the only one showing a real epithelial phenotype. Besides classic chordoma, so-called chondroid chordoma was described as a specific entity showing cartilage-like tissue within chordomatoid structures. However, since its first description, strongly conflicting results have been reported about the existence of chondroid chordoma and several studies suggested chondroid chordomas being in fact low-grade conventional chondrosarcomas. In the present study, we used cytoprotein expression profiling and molecular in situ localization techniques of marker gene products indicative of developmental phenotypes of chondrocytes to elucidate origin and biology of chondroid chordoma. We were able to demonstrate the chondrogenic potential of chordomas irrespectively of the appearance of overt cartilage formation by identifying the multifocal expression of type II collagen, the main marker of chondrocytic differentiation. Additionally, the cartilage-typical large aggregating proteoglycan aggrecan was present throughout all chordomas and, thus, a very characteristic gene product and marker of these neoplasms. Biochemical matrix composition and cell differentiation pattern analysis showed a high resemblance of classic chordomas and in chordoid areas of chondroid chordomas to the fetal chorda dorsalis, whereas chondroid areas of chondroid chordomas showed features similar to adult nucleus pulposus. This demonstrates on the cell function level the chondrocytic differentiation potential of neoplastic chordoid cells as a characteristic facet of chordomas, mimicking fetal vertebral development, ie, the transition of the chorda dorsalis to the nucleus pulposus. Our study firmly establishes a focal real chondrocytic phenotype of neoplastic cells in chordomas. Chondroid chordoma is neither a low-grade chondrosarcoma nor a misnomer as discussed previously.
Gottschalk
D
D
Department of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany.
Fehn
M
M
Patt
S
S
Saeger
W
W
Kirchner
T
T
Aigner
T
T
D053674:Aggrecans; D002454:Cell Differentiation; D002817:Chordoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D003094:Collagen / Q000235:genetics; D016326:Extracellular Matrix Proteins / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007403:Intervertebral Disc / Q000196:embryology / Q000473:pathology*; D007633:Keratins / Q000032:analysis; D037181:Lectins, C-Type; D008159:Lumbar Vertebrae / Q000737:chemistry / Q000196:embryology / Q000473:pathology; D018396:Mucin-1 / Q000032:analysis; D010641:Phenotype; D011509:Proteoglycans / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D009418:S100 Proteins / Q000032:analysis; D014746:Vimentin / Q000032:analysis
D053674:Aggrecans; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D018396:Mucin-1; D011509:Proteoglycans; D012333:RNA, Messenger; D009418:S100 Proteins; D014746:Vimentin; D007633:Keratins; D003094:Collagen